Receive The Newest Study Notifications

AstraZeneca and Merck’s LYNPARZA Added to Bevacizumab Reduced the Risk of Disease Progression or Death by 41% in the Overall Trial Population of Women Who Responded to Platinum-Based Chemotherapy KENILWORTH, N.J.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE: MRK),...

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today presented preliminary results from its ongoing Phase 2 basket trial, evaluating DPX-Survivac in combination with Merck’s Keytruda®...

– TIBSOVO® Reduced the Risk of Disease Progression or Death by 63% (HR=0.37, p<0.001); Median PFS for Patients Randomized to TIBSOVO® was 2.7 months Compared to 1.4 Months with Placebo – – TIBSOVO® Patients Had 6-month PFS Rate of 32% and 12-month PFS Rate of 22%;...

SALT LAKE CITY, Sept. 29, 2019 /PRNewswire/ -- Elevar Therapeutics announced data from the ANGEL trial, a randomized phase 3 study of rivoceranib (also known as apatinib) plus best supportive care in patients with gastric or gastroesophageal junction cancer who have...

ROCKVILLE, Md., Sept. 30, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that GtreeBNT, its Korean...

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., leading the transformation of clinical trials with a digital trials platform connecting patients, sites, and clinical trial teams, will demonstrate a number of integrated eClinical, telemedicine, and data management...

AVID200 is a first-in-class, rationally designed inhibitor of TGF-beta 1 & 3, the main oncogenic TGF-beta isoforms AVID200 demonstrated peripheral target engagement in a Phase 1 clinical trial in solid tumors AVID200 is undergoing additional Phase 1 testing in...

Oragenics, Inc. (NYSE American:OGEN) (“Oragenics”), a leader in the development of novel antibiotics against infectious diseases and effective treatments for oral mucositis, today announces initial data from its ongoing Phase 2, placebo-controlled, clinical trial of...

Interim analysis conducted with first two patients to complete 16-week (Day 113) ANB019 monotherapy study Both patients achieved the primary endpoint of disease score improvement at Day 29 and Day 113 without requiring rescue therapy Patients demonstrated rapid and...

The Global Antibiotic Research and Development Partnership (GARDP), a not for profit organisation developing new treatments for drug resistant infections, and Entasis Therapeutics (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and...

Analyses of two international clinical trials predict response to asthma drug benralizumab by subpopulation of patients with COPD Chronic obstructive pulmonary disease, or COPD, is the third leading cause of death in the U.S., according to the American Lung...

Results from a study sponsored by Stemedica Cell Technologies, Inc., a global biotechnology company that uses allogeneic stem cells for ischemic conditions, form the basis for a peer-reviewed paper published in Stroke entitled "Phase I/II Study of Safety and...

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has commenced pre-screening patients to determine eligibility for ENHANCE-IT, its Phase 2 head-to-head pharmacodynamic (PD) study of MAT9001 against...

Excellent safety results seen in CF patients, with CFA in line with previous studies and no need for a protease Management to discuss the results on a call scheduled for today, September 25, 2019 at 8:30 a.m. Eastern Time NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) --...

MIT study explores the key factors behind patient outcomes in clinical trials evaluating new treatments for non-small-cell lung cancer In a new study just published in JCO Clinical Cancer Informatics, researchers from the Massachusetts Institute of Technology applied...

Treos Bio Limited, which is developing personal cancer vaccines combined with companion diagnostic devices, reported updated positive results on the second part of its phase 1/2 study (OBERTO) with the PolyPEPI1018 cancer vaccine as an add-on to maintenance therapy in...

89bio, Inc. (89bio or the company), a clinical-stage biopharmaceutical company, has initiated dosing in its proof of concept Phase 1b/2a clinical trial evaluating its product candidate, BIO89-100, in patients with nonalcoholic steatohepatitis (NASH) or patients with...

ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces it has enrolled its first patient for the Phase II clinical trial of its lead product CD8 tracer, 89Zr-Df-IAB22M2C, at the O'Neal Comprehensive Cancer Center at the University of Alabama...

BMN 307 Represents a Potential 3rd PKU Treatment Option in BioMarin's PKU Franchise 2nd Gene Therapy Program in Product Pipeline BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a pioneer in treatments for rare disease Phenylketonuria (PKU) and in gene therapies, today...

 In the digital age, Search Engine Optimization (SEO) provides companies with ample opportunity to increase business. If a business is not utilizing SEO, they are doing themselves a disservice. For example, for a clinical trials recruitment agency, SEO provides the...